R
Robert Reindollar
Researcher at Carolinas Medical Center
Publications - 38
Citations - 10640
Robert Reindollar is an academic researcher from Carolinas Medical Center. The author has contributed to research in topics: Ribavirin & Hepatitis C. The author has an hindex of 22, co-authored 38 publications receiving 10510 citations.
Papers
More filters
Journal ArticleDOI
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Michael P. Manns,John G. McHutchison,Stuart C. Gordon,Vinod K. Rustgi,Mitchell L. Shiffman,Robert Reindollar,Zachary Goodman,Kenneth Koury,Mei Hsiu Ling,Janice K. Albrecht +9 more
TL;DR: In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 microg/kg per week plus ribavirin, and this randomised trial found that the benefit is mostly achieved in patients with HCV genotype 1 infections.
Journal ArticleDOI
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
E. J. Heathcote,Mitchell L. Shiffman,W. G. E. Cooksley,Geoffrey Dusheiko,Sam Lee,L. Balart,Robert Reindollar,Rajender Reddy,Teresa L. Wright,A. Lin,Joseph Hoffman,J. de Pamphilis +11 more
TL;DR: In patients with chronic hepatitis C and cirrhosis or bridging fibrosis, 180 microg of peginterferon alfa-2a administered once weekly is significantly more effective than 3 million units of standard interferonAlfa- 2a administered three times weekly.
Journal ArticleDOI
Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
Alexander J. Thompson,Andrew J. Muir,Andrew J. Muir,Mark S. Sulkowski,Dongliang Ge,Jacques Fellay,Kevin V. Shianna,Thomas J. Urban,Nezam H. Afdhal,Ira M. Jacobson,Rafael Esteban,Fred Poordad,Eric Lawitz,Jonathan McCone,Mitchell L. Shiffman,Greg Galler,William M. Lee,Robert Reindollar,John W. King,Paul Y. Kwo,Reem Ghalib,B. Freilich,L. Nyberg,Stefan Zeuzem,Thierry Poynard,David M. Vock,Karen S. Pieper,Keyur Patel,Keyur Patel,Hans L. Tillmann,Hans L. Tillmann,Stephanie Noviello,Kenneth Koury,Lisa D. Pedicone,Clifford A. Brass,Janice K. Albrecht,David Goldstein,John G. McHutchison,John G. McHutchison +38 more
TL;DR: In treatment-naive HCV-1 patients treated with pegylated interferon and ribavirin, a polymorphism upstream of IL-28B is associated with increased on-treatment and sustained virologic response and effectively predicts treatment outcome.
Journal ArticleDOI
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
Anna S. Lok,David F. Gardiner,Eric Lawitz,Claudia Martorell,Gregory T. Everson,Reem Ghalib,Robert Reindollar,Vinod K. Rustgi,Fiona McPhee,Megan Wind-Rotolo,Anna Persson,Kurt Zhu,Dessislava Dimitrova,Timothy Eley,Tong Guo,Dennis M. Grasela,Claudio Pasquinelli +16 more
TL;DR: This preliminary study involving patients with chronic HCV genotype 1 infection who had not had a response to prior therapy showed that a sustained virologic response can be achieved with two direct-acting antiviral agents only.
Journal ArticleDOI
Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C☆
K. Rajender Reddy,Teresa L. Wright,Paul J. Pockros,Mitchell L. Shiffman,Gregory T. Everson,Robert Reindollar,Michael W. Fried,Preston P. Purdum,Donald M. Jensen,C. Smith,William M. Lee,Thomas D. Boyer,A. Lin,Simon Pedder,Jean DePamphilis +14 more
TL;DR: Once‐weekly PEG(40kd) IFN α‐2a was associated with a higher number of sustained virological responses compared with IFNalpha 3 times weekly in patients with chronic hepatitis C, but had a similar safety profile.